Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
Kymera Therapeutics Inc (NASDAQ: KYMR) closed the day trading at $30.20 down -0.17% from the previous closing price of $30.25. In other words, the price has decreased by -$0.17 from its previous closing price. On the day, 0.56 million shares were traded.
Ratios:
For a better understanding of KYMR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.49 and its Current Ratio is at 8.49. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 13, 2025, initiated with a Buy rating and assigned the stock a target price of $52.
On December 10, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $60.
On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Market Perform rating and target price of $55.BMO Capital Markets initiated its Market Perform rating on December 06, 2024, with a $55 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 03 ’25 when Chiniara Ellen sold 2,241 shares for $30.45 per share. The transaction valued at 68,239 led to the insider holds 80,085 shares of the business.
Chadwick Jeremy G sold 1,383 shares of KYMR for $42,113 on Mar 03 ’25. The Chief Operating Officer now owns 67,800 shares after completing the transaction at $30.45 per share. On Mar 03 ’25, another insider, Jacobs Bruce N., who serves as the Chief Financial Officer of the company, sold 7,035 shares for $30.45 each. As a result, the insider received 214,219 and left with 201,886 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 33.40 while its Price-to-Book (P/B) ratio in mrq is 2.50.
Stock Price History:
Over the past 52 weeks, KYMR has reached a high of $53.27, while it has fallen to a 52-week low of $19.44. The 50-Day Moving Average of the stock is 1.09%, while the 200-Day Moving Average is calculated to be -24.40%.
Shares Statistics:
A total of 65.11M shares are outstanding, with a floating share count of 53.16M. Insiders hold about 18.37% of the company’s shares, while institutions hold 95.20% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from 15.0 analysts. The consensus estimate for the next quarter is -$0.93, with high estimates of -$0.59 and low estimates of -$1.26.
Analysts are recommending an EPS of between -$2.61 and -$4.72 for the fiscal current year, implying an average EPS of -$3.63. EPS for the following year is -$4.02, with 16.0 analysts recommending between -$1.91 and -$5.4.
Revenue Estimates
A total of 19 analysts have provided revenue estimates for KYMR’s current fiscal year. The highest revenue estimate was $125.6M, while the lowest revenue estimate was $22.1M, resulting in an average revenue estimate of $67.42M. In the same quarter a year ago, actual revenue was $47.07M
